Literature DB >> 16905692

Role of interleukin 6 in a murine model of Crohn's ileitis: are cytokine/anticytokine strategies the future for IBD therapies?

T T Pizarro1, S A De La Rue, F Cominelli.   

Abstract

Although the precise causes of inflammatory bowel disease (IBD) have yet to be discovered, important therapeutic advances have resulted from the manipulation of cytokine function(s) using anticytokine/cytokine therapies, such as targeting of tumor necrosis factor. We discuss the future of this area of investigation in the context of preclinical experimentation using animal models of IBD. In particular, we pinpoint the roles played by interleukin 6 and its intracellular signalling pathways in the SAMP1/Yit murine model of Crohn's-like ileitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905692      PMCID: PMC1860037          DOI: 10.1136/gut.2005.083121

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  20 in total

1.  The effects of infliximab maintenance therapy on health-related quality of life.

Authors:  Brian G Feagan; Songkai Yan; Mohan Bala; Weihang Bao; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2003-10       Impact factor: 10.864

2.  Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease.

Authors:  W J Sandborn; E V Loftus
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

3.  Emergence of perianal fistulizing disease in the SAMP1/YitFc mouse, a spontaneous model of chronic ileitis.

Authors:  Jesús Rivera-Nieves; Giorgos Bamias; Alda Vidrich; Marco Marini; Theresa T Pizarro; Marcia J McDuffie; Christopher A Moskaluk; Steven M Cohn; Fabio Cominelli
Journal:  Gastroenterology       Date:  2003-04       Impact factor: 22.682

4.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.

Authors:  R Atreya; J Mudter; S Finotto; J Müllberg; T Jostock; S Wirtz; M Schütz; B Bartsch; M Holtmann; C Becker; D Strand; J Czaja; J F Schlaak; H A Lehr; F Autschbach; G Schürmann; N Nishimoto; K Yoshizaki; H Ito; T Kishimoto; P R Galle; S Rose-John; M F Neurath
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

Review 5.  The immunology of mucosal models of inflammation.

Authors:  Warren Strober; Ivan J Fuss; Richard S Blumberg
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

6.  Interleukin-10-deficient mice develop chronic enterocolitis.

Authors:  R Kühn; J Löhler; D Rennick; K Rajewsky; W Müller
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

7.  A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease.

Authors:  Hiroaki Ito; Masakazu Takazoe; Yoshihiro Fukuda; Toshifumi Hibi; Kazuo Kusugami; Akira Andoh; Takayuki Matsumoto; Takehira Yamamura; Junichi Azuma; Norihiro Nishimoto; Kazuyuki Yoshizaki; Takashi Shimoyama; Tadamitsu Kishimoto
Journal:  Gastroenterology       Date:  2004-04       Impact factor: 22.682

8.  Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain.

Authors:  S Matsumoto; Y Okabe; H Setoyama; K Takayama; J Ohtsuka; H Funahashi; A Imaoka; Y Okada; Y Umesaki
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

Review 9.  Mouse models for the study of Crohn's disease.

Authors:  Theresa T Pizarro; Kristen O Arseneau; Giorgos Bamias; Fabio Cominelli
Journal:  Trends Mol Med       Date:  2003-05       Impact factor: 11.951

Review 10.  Optimizing anti-TNF treatment in inflammatory bowel disease.

Authors:  Paul Rutgeerts; Gert Van Assche; Séverine Vermeire
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682

View more
  7 in total

1.  Adenosine A2A receptor contributes to the anti-inflammatory effect of the fixed herbal combination STW 5 (Iberogast®) in rat small intestinal preparations.

Authors:  Sebastian Michael; Heba Abdel-Aziz; Dieter Weiser; Christa E Müller; Olaf Kelber; Karen Nieber
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-12-10       Impact factor: 3.000

2.  The immunobiology of colitis and cholangitis in interleukin-23p19 and interleukin-17A deleted dominant negative form of transforming growth factor beta receptor type II mice.

Authors:  Yugo Ando; Guo-Xiang Yang; Masanobu Tsuda; Kazuhito Kawata; Weici Zhang; Takahiko Nakajima; Koichi Tsuneyama; Patrick Leung; Zhe-Xiong Lian; Kazuichi Okazaki; William M Ridgway; Gary L Norman; Aftab A Ansari; Xiao-Song He; Ross L Coppel; M Eric Gershwin
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

3.  Involvement of a Stat3 binding site in inflammation-induced enteric apelin expression.

Authors:  Song Han; Guiyun Wang; Xiang Qi; Ella W Englander; George H Greeley
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-09-25       Impact factor: 4.052

4.  Food derived carbonyl compounds affect basal and stimulated secretion of interleukin-6 and -8 in Caco-2 cells.

Authors:  Sabine Kuntz; Silvia Rudloff; Julia Ehl; Reinhard G Bretzel; Clemens Kunz
Journal:  Eur J Nutr       Date:  2009-06-21       Impact factor: 5.614

5.  Effect of Cyperus Rotundus on Cytokine Gene Expression in Experimental Inflammatory Bowel Disease.

Authors:  Sarika Johari; Chaitanya Joshi; Tejal Gandhi
Journal:  Iran J Med Sci       Date:  2016-09

6.  Mechanisms of Paeonia lactiflora in Treatment of Ulcerative Colitis: A Network Pharmacological Study.

Authors:  Yin Zhang; Xiaoyan Li; Xianlin Xu; Ningxi Yang
Journal:  Med Sci Monit       Date:  2019-10-09

7.  Molecular Targets and Mechanisms of Scutellariae radix-Coptidis rhizoma Drug Pair for the Treatment of Ulcerative Colitis Based on Network Pharmacology and Molecular Docking.

Authors:  Kai Niu; Qifang Li; Yuan Liu; Yi Qiao; Bingbing Li; Chao Wei; Kunrui Wang; Lu'an Cui; Canlei Zheng; Rong Wang; Li Zhang; Honghua Zhang; Bing Sun; Bin Yu
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-04       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.